Two oral antiviral medications, nirmatrelvir with ritonavir and molnupiravir, were recently authorized for emergency use to treat certain non-hospitalized patients with confirmed COVID-19. Join us for this one-hour webinar to learn about the clinical trial data supporting the emergency-use authorizations of these antivirals. Speakers will also discuss the clinical considerations of each therapy, including precautions and contraindications, and how these antivirals fit into outpatient COVID-19 treatment regimens.
Learning Objectives
- Describe the use of nirmatrelvir/ritonavir and molnupiravir in the treatment of COVID-19.
- Describe contraindications and precautions of nirmatrelvir/ritonavir and molnupiravir therapy for COVID-19.
Faculty
Monica Mahoney, Pharm.D., BCPS, BCIDP, FCCP
Clinical Pharmacy Specialist
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dr. Monica Mahoney is a graduate of MCPHS University Boston, and completed PGY1 and PGY2-ID training at Tufts Medical Center. She is a clinical pharmacy specialist in the outpatient infectious diseases and OPAT clinics at Beth Israel Deaconess Medical Center. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, SIDP, and IDSA. You can find her on Twitter under the handle @mmPharmD.
Molly Miller, Pharm.D.
Clinical Pharmacist
Nebraska Medicine
Omaha, Nebraska
Dr. Molly Miller is a clinical pharmacist in infectious diseases, antimicrobial stewardship, and outpatient parenteral antimicrobial therapy at Nebraska Medicine. Dr. Miller received her Bachelor of Arts in Chemistry in 2015 from the University of Nebraska - Lincoln and her Doctor of Pharmacy degree from the University of Nebraska Medical Center in 2019. She completed her PGY1 pharmacy practice residency and her PGY2 infectious diseases specialty residency at Nebraska Medicine.
Jeremy Tigh, Pharm.D.
PGY2 Specialty Practice Resident
Nebraska Medicine
Omaha, Nebraska
Dr. Jeremy Tigh received a BS in Cell/Molecular Biology from Utah State University and went on to get his Pharm.D. from the University of Utah in 2020. He completed a PGY1 residency at Nebraska Medicine, where he is also a current PGY2 resident in infectious diseases.
Moderator
Michael Ganio, Pharm.D., M.S., FASHP
Senior Director of of Pharmacy Practice and Quality
ASHP's Office of Practice Advancement
Bethesda, Maryland
Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master's degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Prior to becoming the Senior Director of Pharmacy Practice and Quality in ASHP's Office of Practice Advancement, Dr. Ganio's previous roles included clinical pharmacy practice, pharmacy informatics and technology, and outpatient oncology operations. He has extensive knowledge of drug shortage management, pharmacy informatics and automation, medication billing and reimbursement, sterile compounding, and outpatient infusion and ambulatory-care practice models. Dr. Ganio has been invited to speak at several national and international conferences, including several meetings at the National Academies of Medicine on topics related to drug shortages and supply-chain challenges.
Target Audience
This activity was planned to meet the educational needs of pharmacists seeking information on clinical use of nirmatrelvir/ritonavir and molnupiravir for COVID-19 treatment.
CPE Information
ACPE Activity Number: 0204-0000-22-039-L01-P
Activity Type: Application-based
CE Credits: 1.0 contact hour (0.1 CEU)
Activity Fee: Free of charge
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Join the Live Broadcast
- Join the live interactive webinar using your computer or smart device.
- Watch for a confirmation email with additional instructions.
- Get the app and view system requirements
Claim CE Within 60 Days
- Claim CE (enter the CE code announced during activity and complete the evaluation).
- Verify credit has posted to your NABP eProfile account before the 60-day deadline.
- After ACPE's 60-day deadline, ASHP will no longer be able to report credits.
Provided by ASHP